Insulin Dose Reduction When Starting Tirzepatide (Mounjaro)
When initiating tirzepatide in patients on insulin glargine (Lantus) and insulin lispro (Humalog), reduce the basal insulin dose by 20% at the start, and consider reducing or discontinuing the prandial insulin entirely if the baseline HbA1c is ≤8.0%. 1
Initial Dose Adjustments
For Basal Insulin (Lantus/Glargine):
- Reduce insulin glargine by 20% at tirzepatide initiation if baseline HbA1c ≤8.0% 1
- If baseline HbA1c >8.0%, a smaller reduction or no initial reduction may be appropriate, but close monitoring is essential
- The FDA label specifically recommends considering dose reduction of concomitantly administered insulin to reduce hypoglycemia risk 1
For Prandial Insulin (Humalog/Lispro):
- Consider discontinuing or significantly reducing prandial insulin when starting tirzepatide 2
- In the SURPASS-6 trial, tirzepatide replaced prandial insulin lispro entirely while maintaining basal insulin, demonstrating superior glycemic control with significantly less hypoglycemia (0.4 vs 4.4 events per patient-year) 2
- If you choose to continue prandial insulin initially, reduce each dose by at least 50% and titrate based on glucose monitoring
Evidence-Based Rationale
The clinical trial data strongly supports aggressive insulin reduction. In SURPASS-5, when tirzepatide was added to basal insulin, the mean insulin glargine dose actually decreased from baseline (32-35 units/day) to week 40 (29-38 units/day for tirzepatide groups vs 59 units/day for placebo) 1. More importantly, recent real-world data shows that patients transitioning from GLP-1 agonists to tirzepatide required a median 9.2% reduction in total daily insulin, with those having baseline HbA1c ≤8.0% requiring even larger reductions (-22.6%) 3.
Ongoing Titration Strategy
Weeks 1-4:
- Monitor fasting and pre-meal glucose closely (daily initially)
- If fasting glucose drops below 110 mg/dL, reduce basal insulin by an additional 10-20%
- If experiencing any hypoglycemia (<70 mg/dL), reduce basal insulin by 20-40% immediately 4
Weeks 4-12:
- Continue tirzepatide dose escalation per standard protocol (5 mg → 10 mg → 15 mg every 4 weeks)
- With each tirzepatide dose increase, reassess insulin needs
- Expect further insulin dose reductions as tirzepatide reaches higher doses 5, 3
- Target fasting glucose <110 mg/dL without hypoglycemia 4
After Week 12:
- Most insulin dose reduction occurs within the first 2 months; further changes are typically modest 6
- If HbA1c remains above target after 3-6 months on maximum tirzepatide dose, consider adding back small doses of prandial insulin rather than increasing basal insulin excessively 7, 8
Critical Pitfalls to Avoid
Hypoglycemia risk is highest in patients with:
- Baseline HbA1c ≤8.0% (require more aggressive insulin reduction) 3
- Younger age (<65 years) 5
- Longer diabetes duration (≥10 years) 5
- Those already on sulfonylureas (discontinue these entirely) 1
Do NOT continue sulfonylureas when starting tirzepatide—the FDA label explicitly warns about this combination increasing hypoglycemia risk 1. The 2023 ADA guidelines support discontinuing sulfonylureas when intensifying to GLP-1 receptor agonists or dual agonists 9.
Patient-Specific Considerations
For patients with baseline HbA1c >8.5%, you may be more conservative with initial insulin reduction (10% instead of 20%), but still monitor closely as tirzepatide's glucose-lowering effect is substantial—achieving mean HbA1c reductions of 2.1-2.6% across trials 1, 2, 10.
The gastrointestinal side effects of tirzepatide (nausea 14-26%, diarrhea 11-15%) are typically mild-to-moderate and occur early, which is why the 4-week dose escalation schedule is important 1, 2. These effects do not necessitate insulin dose adjustments but may affect carbohydrate intake temporarily.